PARP Inhibitors for BRCA-Linked Prostate Cancer Explained
PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.
hrr gene mutation
PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.